Medicinal Chemistry Support Program for Therapeutic Development
Contract Opportunity Analysis
The National Institute on Neurological Disorders and Stroke and the NIH Blueprint Neurotherapeutics Network intend to modify a sole-award IDIQ contract with Curia Global, Inc. to increase the contract ceiling for the Medicinal Chemistry Support Program for Therapeutic Development and continue support for therapeutic development. The work covers medicinal chemistry services including project management, compound logistics, storage and distribution, synthesis, computational chemistry, in vitro ADMET studies, compound registration, and related reporting and communications. The contract supports ongoing and planned preclinical drug discovery efforts aimed at advancing candidate compounds toward PK and toxicology evaluation in preparation for IND filings, and the ordering period remains March 16, 2018 through March 15, 2028. Interested parties may submit capability statements or objections by 1:00 p.m. EDT on June 4, 2026, referencing notice number HHSN271201800001ISB and emailing Shaun Rostad at shaun.rostad@nih.gov.